{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:57:19Z","timestamp":1787507839257,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with supraventricular tachycardia (SVT) often experience multiple clinical symptoms that require emergency treatment. This study utilized BioMedGPT-LM-7B, an artificial intelligence (AI) model, to comprehensively evaluate the efficacy and adverse effects of adenosine\/adenosine triphosphate (ATP) versus calcium channel blockers (CCBs) in SVT treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study conducted a comprehensive search of multiple medical databases, as well as major trial registries up to December 2024. We performed dual screening and assessment using BioMedGPT-LM-7B and the traditional Cochrane bias risk tool. The primary outcomes were the rate of sinus rhythm restoration and major adverse events, while secondary outcomes included time to restoration, relapse to SVT post-reversion, and any minor adverse events. Outcome measurements were based on odds ratios (OR) and Mean Difference (MD), with the quality of primary outcomes assessed using the GRADE method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study included 10 RCTs with a total of 960 SVT patients admitted to the emergency department. Comparing BioMedGPT-LM-7B with the traditional Cochrane bias risk tool, we found no significant differences in random sequence generation and selective reporting. Moderate evidence showed no difference between adenosine\/ATP and CCBs in restoring sinus rhythm (OR\u2009=\u20091.44, 95% CI [0.89,2.34]), but adenosine\/ATP had a shorter time to reversion (MD\u2009=\u2009423,24, 95% CI [293.54, 552.93]). However, the research findings show a lower level of evidence regarding differences in side effects among the drugs mentioned above. Three cases of hypotension were reported in the CCB group, whereas none were reported in the adenosine group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Adenosine\/ATP and CCBs have similar efficacy in treating SVT, but adenosine\/ATP has a shorter conversion time and no reported cases of hypotension. Clinical studies indicate that adenosine has a higher success rate and faster conversion time in restoring sinus rhythm compared to ATP, with milder side effects. However, further prospective studies are needed to evaluate patient experience and potential adverse events, ensuring a more comprehensive understanding of treatment safety and efficacy. Additionally, this study showcases BioMedGPT-LM-7B\u2019s potential for medical data analysis and future meta-analyses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-025-04595-x","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T02:55:49Z","timestamp":1741316149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of adenosine for supraventricular tachycardia: A meta-analysis utilizing BioMedGPT-LM-7B"],"prefix":"10.1186","volume":"25","author":[{"given":"Xuemei","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"key":"4595_CR1","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1056\/NEJMcp1111259","volume":"367","author":"MS Link","year":"2012","unstructured":"Link MS. Clinical practice. Evaluation and initial treatment of supraventricular tachycardia. N Engl J Med. 2012;367:1438\u201348.","journal-title":"N Engl J Med"},{"key":"4595_CR2","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1161\/01.CIR.0000059743.36226.E8","volume":"107","author":"JD Ferguson","year":"2003","unstructured":"Ferguson JD, DiMarco JP. Contemporary management of paroxysmal supraventricular tachycardia. Circulation. 2003;107:1096\u20139.","journal-title":"Circulation"},{"issue":"4","key":"4595_CR3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/0735-6757(95)90139-6","volume":"13","author":"RB Vukmir","year":"1995","unstructured":"Vukmir RB. Cardiac arrhythmia therapy[J]. Am J Emerg Med. 1995;13(4):459\u201370.","journal-title":"Am J Emerg Med"},{"issue":"9","key":"4595_CR4","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/clc.4960080903","volume":"8","author":"B Belhassen","year":"1985","unstructured":"Belhassen B, Pelleg A. Adenosine triphosphate and adenosine: perspectives in the acute management of paroxysmal supraventricular tachycardia. Clin Cardiol. 1985;8(9):460\u20134. https:\/\/doi.org\/10.1002\/clc.4960080903.","journal-title":"Clin Cardiol"},{"key":"4595_CR5","first-page":"225","volume":"12","author":"JR Hume","year":"2009","unstructured":"Hume JR, Grant AOJB, Pharmacology C, et al. Agents Used Cardiac Arrhythm. 2009;12:225\u201348.","journal-title":"Agents Used Cardiac Arrhythm"},{"issue":"1","key":"4595_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/1753944714553425","volume":"9","author":"H Shaker","year":"2015","unstructured":"Shaker H, Jahanian F, Fathi M, Zare M. Oral verapamil in paroxysmal supraventricular tachycardia recurrence control: a randomized clinical Tria. Ther Adv Cardiovasc Dis. 2015;9(1):4\u20139.","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"4595_CR7","doi-asserted-by":"crossref","unstructured":"Zhang R et al. Diagnosis of coronavirus disease 2019 pneumonia by using chest radiography: value of artificial intelligence. Radiology 298.2 (2021): E88\u201397.","DOI":"10.1148\/radiol.2020202944"},{"key":"4595_CR8","doi-asserted-by":"publisher","first-page":"1169595","DOI":"10.3389\/frai.2023.1169595","volume":"6","author":"T Dave","year":"2023","unstructured":"Dave T, Athaluri SA, Singh S. ChatGPT in medicine: an overview of its applications, advantages, limitations, future prospects, and ethical considerations. Front Artif Intell. 2023;6:1169595.","journal-title":"Front Artif Intell"},{"key":"4595_CR9","doi-asserted-by":"crossref","unstructured":"Marr B. Revolutionizing Healthcare: The Top 14 Uses Of ChatGPT In Medicine And Wellness. (2023).","DOI":"10.37723\/jumdc.v14i2.850"},{"key":"4595_CR10","unstructured":"Doshi RH, Simar S. Bajaj. Promises-and pitfalls-of ChatGPT-assisted medicine. Stat (2023)."},{"key":"4595_CR11","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.2308.09442","author":"Y Luo","year":"2023","unstructured":"Luo Y, Zhang J, Fan S, Yang K, Wu Y, Qiao M, Nie Z. BioMedGPT: open multimodal generative pretrained transformer for biomedicine. ArXiv Preprint arXiv:2308 09442. 2023. https:\/\/doi.org\/10.48550\/arXiv.2308.09442.","journal-title":"ArXiv Preprint arXiv:2308 09442"},{"key":"4595_CR12","unstructured":"Athar M, Majid A, Hussain A et al. COMPARISON OF EFFICACY OF INTRAVENOUS ADENOSINE AND VERAPAMIL IN ACUTE PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA IN ADULTS."},{"key":"4595_CR13","unstructured":"Riaz R, Mishra J, Hussain S et al. Adenosine versus verapamil for the treatment of supra-ventricular tachycardia: randomized comparative trail. 2012;6:541\u20133."},{"key":"4595_CR14","doi-asserted-by":"crossref","unstructured":"Higgins J, Thompson SG, Deeks JJ et al. cochrane handbook for systematic reviews of interventions version 5.1.0. the cochrane collaboration. 2008;5:S38.","DOI":"10.1002\/9780470712184"},{"key":"4595_CR15","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1161\/01.CIR.66.3.504","volume":"66","author":"R Greco","year":"1982","unstructured":"Greco R, Musto B, Arienzo V, et al. Treatment of paroxysmal supraventricular tachycardia in infancy with digitalis, adenosine-5\u2019-triphosphate, and verapamil: a comparative study. Circulation. 1982;66:504\u20138.","journal-title":"Circulation"},{"key":"4595_CR16","doi-asserted-by":"crossref","unstructured":"Lim SH, Anantharaman V, Teo WS et al. Slow infusion of calcium channel blockers compared with intravenous adenosine in the emergency treatment of supraventricular tachycardia. 2009;80:523\u20138.","DOI":"10.1016\/j.resuscitation.2009.01.017"},{"key":"4595_CR17","unstructured":"Cabrera-Sole R, Abeytua M, Bescos LL et al. Paroxysmal supraventricular tachycardia: efficacy of adenosine versus verapamil. 1989."},{"key":"4595_CR18","first-page":"55","volume":"66","author":"JFM Ferreira","year":"1996","unstructured":"Ferreira JFM, Pamplona D, Cesar LAM, et al. Adenosin-three phosphate compared with verapamil to treat paroxysmal supraventricular tachycardia. Arquivos Brasileros De Cardiologia. 1996;66:55\u20137.","journal-title":"Arquivos Brasileros De Cardiologia"},{"key":"4595_CR19","first-page":"773","volume":"42","author":"KA Cheng","year":"2003","unstructured":"Cheng KA. A randomized, multicenter trial to compare the safety and efficacy of adenosine versus verapamil for termination of paroxysmal supraventricular tachycardia. Zhonghua Nei Ke Za Zhi. 2003;42:773\u20136.","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"4595_CR20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.plefa.2006.03.005","volume":"74","author":"II Vranic","year":"2006","unstructured":"Vranic II, Matic M, Perunicic J, et al. Adenosine cardioprotection study in clinical setting of paroxysmal supraventricular tachycardia. Prostaglandins Leukot Essent Fat Acids. 2006;74:365\u201371.","journal-title":"Prostaglandins Leukot Essent Fat Acids"},{"key":"4595_CR21","unstructured":"Merch\u00e1n JGMSLR. G, Adenosin triphosphate and the treatment of paroxysmal supraventricular tachycardia: A comparison with verapamil. 1995;48:55\u20138."},{"key":"4595_CR22","doi-asserted-by":"publisher","unstructured":"Ma Yue,Yu Yan,Wang Lixin. Comparative study on drug treatment of paroxysmal supraventricular tachycardia [J]. Chinese and foreign medical treatment,2011,30 (10):105\u20136.https:\/\/doi.org\/10.16662\/j.cnki.1674-0742.2011.10.076","DOI":"10.16662\/j.cnki.1674-0742.2011.10.076"},{"key":"4595_CR23","unstructured":"Li Z. Clinical observation of supraventricular tachycardia treated with adenosine[J]. J Shanxi Workers\u2019 Med Coll 2005,15 (3):22\u20133."},{"issue":"18","key":"4595_CR24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.12677\/TCM.2013.24011","volume":"32","author":"wuwei Wang","year":"2013","unstructured":"Wang wuwei, Zhang yongxiang, Zhang Ling. A controlled study on the clinical safety of verapamil and adenosine in aborting paroxysmal supraventricular tachycardia[J]. Inner Mongolia Traditional Chin Med. 2013;32(18):43\u201343.","journal-title":"Inner Mongolia Traditional Chin Med"},{"key":"4595_CR25","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/S0002-8703(05)80022-5","volume":"119","author":"AC Rankin","year":"1990","unstructured":"Rankin AC, Olclroyd KG, Chong E, et al. Adenosine or adenosine triphosphate for supraventricular tachycardias comparative double-blind randomized study in patients with spontaneous or inducible arrhythmias. Am Heart J. 1990;119:316\u201323.","journal-title":"Am Heart J"},{"issue":"5","key":"4595_CR26","first-page":"323","volume":"15","author":"F Liu","year":"2001","unstructured":"Liu F, Yubao F. Clinical observation of adenosine in terminating paroxysmal supraventricular tachycardia [J]. Chin J Cardiac Pacing Electrophysiol. 2001;15(5):323.","journal-title":"Chin J Cardiac Pacing Electrophysiol"},{"issue":"Suppl 1","key":"4595_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11302-011-9268-1","volume":"8","author":"A Pelleg","year":"2012","unstructured":"Pelleg A, Kutalek SP, Flammang D, Benditt D. ATPace\u2122: injectable adenosine 5\u2019-triphosphate: diagnostic and therapeutic indications. Purinergic Signal. 2012;8(Suppl 1):57\u201360.","journal-title":"Purinergic Signal"},{"issue":"9","key":"4595_CR28","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/clc.4960080903","volume":"8","author":"B Belhassen","year":"1985","unstructured":"Belhassen B, Pelleg A. Adenosine\u2002triphosphate\u2002and\u2002adenosine: perspectives in the acute management of paroxysmal supraventricular tachycardia. Clin Cardiol. 1985;8(9):460\u20134.","journal-title":"Clin Cardiol"},{"issue":"16Suppl2","key":"4595_CR29","first-page":"S366","volume":"142","author":"AR Panchal","year":"2020","unstructured":"Panchal AR, Bartos JA, Caba\u00f1as JG, et al. Part 3: adult basic and advanced life support: 2020 American heart association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care[J]. Circulation. 2020;142(16Suppl2):S366\u2013468.","journal-title":"Circulation"},{"issue":"9","key":"4595_CR30","doi-asserted-by":"publisher","first-page":"e031678","DOI":"10.1136\/bmjopen-2019-031678","volume":"9","author":"M Balik","year":"2019","unstructured":"Balik M, Waldauf P, Maly M, Matousek V, Brozek T, Rulisek J, Porizka M, Sachl R, Otahal M, Brestovansky P, Svobodova E, Flaksa M, Stach Z, Pazout J, Duska F, Smid O, Stritesky M. Efficacy\u2002and\u2002safety\u2002of\u20021\u00a0C\u2002class\u2002antiarrhythmic\u2002agent\u2002 (propafenone) for supraventricular arrhythmias in septic shock compared to Amiodarone: protocol of a prospective randomized double-blind study. BMJ Open. 2019;9(9):e031678.","journal-title":"BMJ Open"},{"key":"4595_CR31","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00508-008-1017-2","volume":"120","author":"A Hofmann","year":"2008","unstructured":"Hofmann A, Nawara C, Ofluoglu S, Holzmannhofer J, et al. Incidence and predictability of amiodarone-induced thyrotoxicosis and hypothyroidism. Wien Klin Wochenschr. 2008;120:493\u20138.","journal-title":"Wien Klin Wochenschr"},{"key":"4595_CR32","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/01.CCM.0000151048.72393.44","volume":"33","author":"AE R\u00e4tz Bravo","year":"2005","unstructured":"R\u00e4tz Bravo AE, Drewe J, Schlienger RG, et al. Hepatotoxicity during rapid intravenous loading with Amiodarone: description of three cases and review of the literature. Crit Care Med. 2005;33:128\u201334.","journal-title":"Crit Care Med"},{"key":"4595_CR33","first-page":"Ud01","volume":"11","author":"VK Singh","year":"2017","unstructured":"Singh VK, Maheshwari V. Acute respiratory distress syndrome complicated by Amiodarone induced pulmonary fibrosis: do not let your guard down. J Clin Diagn Res. 2017;11:Ud01\u20132.","journal-title":"J Clin Diagn Res"},{"key":"4595_CR34","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2165\/11532320-000000000-00000","volume":"33","author":"SA Papiris","year":"2010","unstructured":"Papiris SA, Triantafillidou C, Kolilekas L, et al. Amiodarone: review of pulmonary effects and toxicity. Drug Saf. 2010;33:539\u2013358.","journal-title":"Drug Saf"},{"key":"4595_CR35","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1056\/NEJM199103213241201","volume":"324","author":"DS Echt","year":"1991","unstructured":"Echt DS, Liebson PR, Mitchell LB, Peters RW, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial. N Engl J Med. 1991;324:781\u20138.","journal-title":"N Engl J Med"},{"key":"4595_CR36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0735-1097(02)02705-5","volume":"41","author":"P Chevalier","year":"2003","unstructured":"Chevalier P, Durand-Dubief A, Burri H, Cucherat M, et al. Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. J Am Coll Cardiol. 2003;41:255\u201362.","journal-title":"J Am Coll Cardiol"},{"key":"4595_CR37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.5603\/CJ.2013.0035","volume":"20","author":"P-YN Courand","year":"2013","unstructured":"Courand P-YN, Sibellas F, Ranc S, Mullier A, et al. Arrhythmogenic effect of flecainide toxicity. Cardiol J. 2013;20:203\u20135.","journal-title":"Cardiol J"},{"issue":"6","key":"4595_CR38","first-page":"e15502","volume":"13","author":"F Ahmad","year":"2021","unstructured":"Ahmad F, Abu Sneineh M, Patel RS, Rohit Reddy S, Llukmani A, Hashim A, Haddad DR, Gordon DK. The line of treatment: a\u2002systematic\u2002review\u2002of\u2002paroxysmal\u2002supraventricular\u2002tachycardia. Cureus. 2021;13(6):e15502.","journal-title":"Cureus"},{"key":"4595_CR39","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S0196-0644(95)70179-6","volume":"25","author":"CD Madsen","year":"1995","unstructured":"Madsen CD, Pointer JE, Lynch TG. A comparison of adenosine and verapamil for the treatment of supraventricular tachycardia in the prehospital setting. Ann Emerg Med. 1995;25:649\u201355.","journal-title":"Ann Emerg Med"},{"key":"4595_CR40","doi-asserted-by":"publisher","first-page":"104","DOI":"10.7326\/0003-4819-113-2-104","volume":"113","author":"JP DiMarco","year":"1990","unstructured":"DiMarco JP, Miles W, Akhtar M, et al. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The adenosine for PSVT study group. Ann Intern Med. 1990;113:104\u201310.","journal-title":"Ann Intern Med"},{"key":"4595_CR41","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/0002-8703(92)90807-8","volume":"123","author":"MA Hood","year":"1992","unstructured":"Hood MA, Smith WM. Adenosine versus verapamil in the treatment of supraventricular tachycardia: a randomized double-crossover trial. Am Heart J. 1992;123:1543\u20139.","journal-title":"Am Heart J"},{"key":"4595_CR42","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/j.1553-2712.1996.tb03467.x","volume":"3","author":"WJ Brady Jr","year":"1996","unstructured":"Brady WJ Jr, DeBehnke DJ, Wickman LL, Lindbeck G. Treatment of out-of-hospital supraventricular tachycardia: adenosine vs verapamil. Acad Emerg Med. 1996;3:574\u201385.","journal-title":"Acad Emerg Med"},{"key":"4595_CR43","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.resuscitation.2009.01.017","volume":"80","author":"SH Lim","year":"2009","unstructured":"Lim SH, Anantharaman V, Teo WS, Chan YH. Slow infusion of calcium channel blockers compared with intravenous adenosine in the emergency treatment of supraventricular tachycardia. Resuscitation. 2009;80:523\u20138.","journal-title":"Resuscitation"},{"key":"4595_CR44","doi-asserted-by":"crossref","unstructured":"Pollack C et al. 485 Healthcare resource use after Etripamil treatment to terminate paroxysmal supraventricular tachycardia: A pooled analysis of phase 3 clinical trials. Annals of emergency medicine 84.4 (2024): S216.","DOI":"10.1016\/j.annemergmed.2024.08.476"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04595-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-04595-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04595-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T02:55:57Z","timestamp":1741316157000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-025-04595-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4595"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-04595-x","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]},"assertion":[{"value":"28 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"158"}}